Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The worldwide Urological Cancer Therapeutics Drugs market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 13.6% during the forecast period.
This report presents the market size and development trends by detailing the Urological Cancer Therapeutics Drugs market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Urological Cancer Therapeutics Drugs market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Urological Cancer Therapeutics Drugs industry and will help you to build a panoramic view of the industrial development.
Urological Cancer Therapeutics Drugs Market, By Type:
Xofigo (radium Ra 223 dichloride)
Jevtana (cabazitaxel)
Inlyta (axitinib)
Votrient (pazopanib hydrochloride)
Sutent (sunitinib malate)
Zytiga (abiraterone acetate)
Xtandi (enzalutamide)
Opdivo (nivolumab)
Provenge (sipuleucel-T)
Urological Cancer Therapeutics Drugs Market, By Application:
Hospital
Medical Research Laboratory
Others
Some of the leading players are as follows:
Dendreon Corporation
Sanofi S.A.
Bristol-Myers Squibb
Pfizer
Roche Healthcare
AstraZeneca
Abbott Laboratories
Ipsen
Celgene Corporation
Ferring Pharmaceuticals
Johnson & Johnson
Novartis
GlaxoSmithKline plc
Indevus Pharmaceuticals Inc
Astellas
Geographically, Major regions are analyzed in details are as follows:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East & Africa
Table of Contents
1 Methodology and Scope
-
1.1 Market Segmentation & Scope
-
1.1.1 Technology Type
-
1.1.2 Product
-
1.1.3 Application
-
1.1.4 Regional scope
-
1.1.5 Estimates and forecast timeline
-
1.2 Research Methodology
-
1.3 Information Procurement
-
1.3.1 Purchased database
-
1.3.2 Internal database
-
1.3.3 Secondary sources
-
1.3.4 Primary research
-
1.3.5 Details of primary research
-
1.4 Information or Data Analysis
-
1.4.1 Data analysis models
-
1.5 Market Formulation & Validation
-
1.6 Model Details
-
1.6.1 Commodity flow analysis
-
1.6.2 Volume price analysis
-
1.7 List of Secondary Sources
-
1.8 List of Abbreviations
2 Executive Summary
-
2.1 Market Outlook
-
2.2 Segment Outlook
3 Market Variables, Trends, & Scope
-
3.1 Market Lineage Outlook
-
3.1.1 Parent market outlook
-
3.1.2 Ancillary market outlook
-
3.2 Market Segmentation
-
3.2.1 Analysis
-
3.3 Market Dynamics
-
3.3.1 Market driver analysis
-
3.3.2 Market restraint analysis
-
3.3.3 Industry opportunities
-
3.4 Penetration & Growth Prospect Mapping
-
3.4.1 Penetration & growth prospect mapping analysis
-
3.5 Business Environment Analysis Tools
-
3.5.1 Porter's five forces analysis
-
3.5.2 PESTLE analysis
-
3.5.3 Major deals & strategic alliances analysis
4 Urological Cancer Therapeutics Drugs Market: Technology Type Analysis
-
4.1 Urological Cancer Therapeutics Drugs Technology Type Market Share Analysis, 2018 & 2026
-
4.2 Urological Cancer Therapeutics Drugs Technology Type Market: Segment Dashboard
-
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment
4.3.1 Xofigo (radium Ra 223 dichloride)
4.3.2 Jevtana (cabazitaxel)
4.3.3 Inlyta (axitinib)
4.3.4 Votrient (pazopanib hydrochloride)
4.3.5 Sutent (sunitinib malate)
4.3.6 Zytiga (abiraterone acetate)
4.3.7 Xtandi (enzalutamide)
4.3.8 Opdivo (nivolumab)
4.3.9 Provenge (sipuleucel-T)
5 Urological Cancer Therapeutics Drugs Market: Product Analysis
-
5.1 Urological Cancer Therapeutics Drugs Product Market Share Analysis, 2018 & 2026
-
5.2 Urological Cancer Therapeutics Drugs Product Market: Segment Dashboard
-
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment
6 Urological Cancer Therapeutics Drugs Market: Application Analysis
-
6.1 Urological Cancer Therapeutics Drugs Application Market Share Analysis, 2018 & 2026
-
6.2 Urological Cancer Therapeutics Drugs Application Market: Segment Dashboard
-
6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment
6.3.1 Hospital
6.3.2 Medical Research Laboratory
6.3.3 Others
7 Urological Cancer Therapeutics Drugs Market: Regional Analysis
-
7.1 Urological Cancer Therapeutics Drugs Regional Market Share Analysis, 2018 & 2026
-
7.2 Urological Cancer Therapeutics Drugs Regional Market: Segment Dashboard
-
7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)
-
7.4 List of Players at Regional Level
-
7.4.1 North America
-
7.4.2 Europe
-
7.4.3 Asia Pacific
-
7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
-
7.5.1 North America
-
7.5.2 Europe
-
7.5.3 Asia Pacific
-
7.5.4 Latin America
-
7.5.5 MEA
-
7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026
-
7.6.1 North America
-
7.6.2 Europe
-
7.6.3 Asia Pacific
-
7.6.4 Latin America
-
7.6.5 Middle East & Africa
8 Competitive Analysis
-
8.1 Recent Developments & Impact Analysis, by Key Market Participants
-
8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)
-
8.3 Vendor Landscape
-
8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)
9 Company Profiles
9.1 Dendreon Corporation
9.1.1 Dendreon Corporation Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.1.5 SWOT analysis
9.2 Sanofi S.A.
9.2.1 Sanofi S.A. Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.2.5 SWOT analysis
9.3 Bristol-Myers Squibb
9.3.1 Bristol-Myers Squibb Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.3.5 SWOT analysis
9.4 Pfizer
9.4.1 Pfizer Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.4.5 SWOT analysis
9.5 Roche Healthcare
9.5.1 Roche Healthcare Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.5.5 SWOT analysis
9.6 AstraZeneca
9.6.1 AstraZeneca Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.6.5 SWOT analysis
9.7 Abbott Laboratories
9.7.1 Abbott Laboratories Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.7.5 SWOT analysis
9.8 Ipsen
9.8.1 Ipsen Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.8.5 SWOT analysis
9.9 Celgene Corporation
9.9.1 Celgene Corporation Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.9.5 SWOT analysis
9.10 Ferring Pharmaceuticals
9.10.1 Ferring Pharmaceuticals Company overview
9.10.2 Financial performance
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.10.5 SWOT analysis
9.11 Johnson & Johnson
9.11.1 Johnson & Johnson Company overview
9.11.2 Financial performance
9.11.3 Product benchmarking
9.11.4 Strategic initiatives
9.11.5 SWOT analysis
9.12 Novartis
9.12.1 Novartis Company overview
9.12.2 Financial performance
9.12.3 Product benchmarking
9.12.4 Strategic initiatives
9.12.5 SWOT analysis
9.13 GlaxoSmithKline plc
9.13.1 GlaxoSmithKline plc Company overview
9.13.2 Financial performance
9.13.3 Product benchmarking
9.13.4 Strategic initiatives
9.13.5 SWOT analysis
9.14 Indevus Pharmaceuticals Inc
9.14.1 Indevus Pharmaceuticals Inc Company overview
9.14.2 Financial performance
9.14.3 Product benchmarking
9.14.4 Strategic initiatives
9.14.5 SWOT analysis
9.15 Astellas
9.15.1 Astellas Company overview
9.15.2 Financial performance
9.15.3 Product benchmarking
9.15.4 Strategic initiatives
9.15.5 SWOT analysis
The List of Tables and Figures (Totals 70 Figures and 126 Tables)
Figure Xofigo (radium Ra 223 dichloride) Urological Cancer Therapeutics Drugs market, 2015 - 2026 (USD Million)
Figure Jevtana (cabazitaxel) Urological Cancer Therapeutics Drugs market, 2015 - 2026 (USD Million)
Figure Inlyta (axitinib) Urological Cancer Therapeutics Drugs market, 2015 - 2026 (USD Million)
Figure Votrient (pazopanib hydrochloride) Urological Cancer Therapeutics Drugs market, 2015 - 2026 (USD Million)
Figure Sutent (sunitinib malate) Urological Cancer Therapeutics Drugs market, 2015 - 2026 (USD Million)
Figure Zytiga (abiraterone acetate) Urological Cancer Therapeutics Drugs market, 2015 - 2026 (USD Million)
Figure Xtandi (enzalutamide) Urological Cancer Therapeutics Drugs market, 2015 - 2026 (USD Million)
Figure Opdivo (nivolumab) Urological Cancer Therapeutics Drugs market, 2015 - 2026 (USD Million)
Figure Provenge (sipuleucel-T) Urological Cancer Therapeutics Drugs market, 2015 - 2026 (USD Million)
Figure Hospital market, 2015 - 2026 (USD Million)
Figure Medical Research Laboratory market, 2015 - 2026 (USD Million)
Figure Others market, 2015 - 2026 (USD Million)
-
Table List of players in North America
-
Table List of players in Europe
-
Table List of players in Asia Pacific
-
Table SWOT analysis
-
Table North America Urological Cancer Therapeutics Drugs market, by country, 2015 - 2026 (USD Million)
-
Table North America Urological Cancer Therapeutics Drugs market, by type, 2015 - 2026 (USD Million)
-
Table North America Urological Cancer Therapeutics Drugs market, by product, 2015 - 2026 (USD Million)
-
Table North America Urological Cancer Therapeutics Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.S. Urological Cancer Therapeutics Drugs market, by type, 2015 - 2026 (USD Million)
-
Table U.S. Urological Cancer Therapeutics Drugs market, by product, 2015 - 2026 (USD Million)
-
Table U.S. Urological Cancer Therapeutics Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Canada Urological Cancer Therapeutics Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Canada Urological Cancer Therapeutics Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Canada Urological Cancer Therapeutics Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Europe Urological Cancer Therapeutics Drugs market, by country, 2015 - 2026 (USD Million)
-
Table Europe Urological Cancer Therapeutics Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Europe Urological Cancer Therapeutics Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Europe Urological Cancer Therapeutics Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.K. Urological Cancer Therapeutics Drugs market, by type, 2015 - 2026 (USD Million)
-
Table U.K. Urological Cancer Therapeutics Drugs market, by product, 2015 - 2026 (USD Million)
-
Table U.K. Urological Cancer Therapeutics Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Germany Urological Cancer Therapeutics Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Germany Urological Cancer Therapeutics Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Germany Urological Cancer Therapeutics Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table France Urological Cancer Therapeutics Drugs market, by type, 2015 - 2026 (USD Million)
-
Table France Urological Cancer Therapeutics Drugs market, by product, 2015 - 2026 (USD Million)
-
Table France Urological Cancer Therapeutics Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Italy Urological Cancer Therapeutics Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Italy Urological Cancer Therapeutics Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Italy Urological Cancer Therapeutics Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Spain Urological Cancer Therapeutics Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Spain Urological Cancer Therapeutics Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Spain Urological Cancer Therapeutics Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Asia Pacific Urological Cancer Therapeutics Drugs market, by country, 2015 - 2026 (USD Million)
-
Table Asia Pacific Urological Cancer Therapeutics Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Asia Pacific Urological Cancer Therapeutics Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Asia Pacific Urological Cancer Therapeutics Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table China Urological Cancer Therapeutics Drugs market, by type, 2015 - 2026 (USD Million)
-
Table China Urological Cancer Therapeutics Drugs market, by product, 2015 - 2026 (USD Million)
-
Table China Urological Cancer Therapeutics Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Japan Urological Cancer Therapeutics Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Japan Urological Cancer Therapeutics Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Japan Urological Cancer Therapeutics Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table India Urological Cancer Therapeutics Drugs market, by type, 2015 - 2026 (USD Million)
-
Table India Urological Cancer Therapeutics Drugs market, by product, 2015 - 2026 (USD Million)
-
Table India Urological Cancer Therapeutics Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Latin America Urological Cancer Therapeutics Drugs market, by country, 2015 - 2026 (USD Million)
-
Table Latin America Urological Cancer Therapeutics Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Latin America Urological Cancer Therapeutics Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Latin America Urological Cancer Therapeutics Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Brazil Urological Cancer Therapeutics Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Brazil Urological Cancer Therapeutics Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Brazil Urological Cancer Therapeutics Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Mexico Urological Cancer Therapeutics Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Mexico Urological Cancer Therapeutics Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Mexico Urological Cancer Therapeutics Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Argentina Urological Cancer Therapeutics Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Argentina Urological Cancer Therapeutics Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Argentina Urological Cancer Therapeutics Drugs market, by application, 2015 - 2026 (USD Million)
-
Table MEA Urological Cancer Therapeutics Drugs market, by country, 2015 - 2026 (USD Million)
-
Table MEA Urological Cancer Therapeutics Drugs market, by type, 2015 - 2026 (USD Million)
-
Table MEA Urological Cancer Therapeutics Drugs market, by product, 2015 - 2026 (USD Million)
-
Table MEA Urological Cancer Therapeutics Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table South Africa Urological Cancer Therapeutics Drugs market, by type, 2015 - 2026 (USD Million)
-
Table South Africa Urological Cancer Therapeutics Drugs market, by product, 2015 - 2026 (USD Million)
-
Table South Africa Urological Cancer Therapeutics Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Nigeria Urological Cancer Therapeutics Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Nigeria Urological Cancer Therapeutics Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Nigeria Urological Cancer Therapeutics Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Company market position analysis
Table Company Profiles
Table Dendreon Corporation Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Sanofi S.A. Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Bristol-Myers Squibb Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Pfizer Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Roche Healthcare Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table AstraZeneca Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Abbott Laboratories Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Ipsen Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Celgene Corporation Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Ferring Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Johnson & Johnson Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Novartis Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table GlaxoSmithKline plc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Indevus Pharmaceuticals Inc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Astellas Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
-
